AMIIF
The Mexican Association of Pharmaceutical Research Industries , AMIIF for its name in Spanish , represents 40 of the top companies focused on the development of innovative medicines that improve expectations of patients worldwide .
AMIIF aims to become a strategic piece for the transformation of the health environment in Mexico based on pharmaceutical innovation . To achieve this objective , it has a strategic plan developed with a holistic approach focused on innovation , investments in health and new links to all stakeholders involved in the health sector development in Mexico .
Pharmaceutical companies represent the second most important industry in this country , as they account for 1.2 percent of Gross Domestic Product ( GDP ), equivalent to almost $ 193 billion pesos , according to data from the Ministry of Economy . Plus , more than 13 percent of the pharmaceutical industry ’ s sales are invested in new research and development projects .
In 2014 , Mexico reached the largest number of innovative medicines approved in the last years , with 32 registries of new molecules . Since the national regulatory agency ( Cofepris for its name in Spanish ) started its current administration in 2012 , Mexico has opened its doors to 133 innovative medicines . The challenge remains on how to ease access to these new therapies , which is a priority for all participants in the Health sector
108 February 2015